If another shortage occurs in the future, its possible the FDA will again allow a temporary expansion of semaglutide compounding
The most common typically strongest in the first 48 weeks as the body adapts include: Nausea (most common, usually dose-dependent) Diarrhoea or constipation Fatigue , especially during dose escalations Mild headache Reflux and acid reflux Loss of appetite (this is the therapeutic effect, not a side effect, but it can be uncomfortable) Less common but more serious effects warranting immediate physician review include pancreatitis, gallbladder disease, and kidney issues, particularly in patients with pre-existing conditions
This 2016 review summarizes various pathways by which IGF and insulin suppression may slow or inhibit tumor growth
FDA was notified by Novo Nordisk on Nov
28,29 Although highly effective, 30 patients must administer injections of exenatide multiple times a day leading to low patient compliance
The safety, risk and anticipated benefit of any medication must be measured against the risk of the underlying disease and potential comorbidities that the medication is intended to treat
)
